Literature DB >> 3598478

Somatization disorder in a family practice.

F deGruy, L Columbia, P Dickinson.   

Abstract

Somatization disorder is a condition characterized by multiple unexplained complaints. This study was done to determine the prevalence of somatization disorder in a family practice office setting, to characterize the patients so affected, and to assess their impact on the practice. A sample of ill patients was interviewed, of whom 6 (5 percent) had definite somatization disorder and another 4 (4 percent) had borderline somatization disorder (ten or more symptoms). All were women, and they were more likely than controls to live in households with children but no spouse (P less than .01). They were also more likely than their unaffected counterparts to be from the lowest two social classes (P less than .01). Compared with matched controls, their rate of office visits and charges incurred was about 50 percent greater (.58 visits per month vs .41 visits per month; $23.28 per month vs $14.44 per month). Their charts were thicker (7 cm vs 3.6 cm) and heavier (3076 g vs 1843 g) and had more diagnoses (85 vs 51) than controls. The physicians of the somatizers were significantly less satisfied with the care rendered to them than to the controls (P less than .01). This study demonstrates that somatization disorder is a prevalent, expensive, and difficult problem for family physicians.

Entities:  

Mesh:

Year:  1987        PMID: 3598478

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  16 in total

Review 1.  Somatization disorder: defining its role in clinical medicine.

Authors:  R C Smith
Journal:  J Gen Intern Med       Date:  1991 Mar-Apr       Impact factor: 5.128

Review 2.  Somatoform disorders and medically unexplained symptoms in primary care.

Authors:  Heidemarie Haller; Holger Cramer; Romy Lauche; Gustav Dobos
Journal:  Dtsch Arztebl Int       Date:  2015-04-17       Impact factor: 5.594

3.  Primary care clinicians treat patients with medically unexplained symptoms: a randomized controlled trial.

Authors:  Robert C Smith; Judith S Lyles; Joseph C Gardiner; Corina Sirbu; Annemarie Hodges; Clare Collins; Francesca C Dwamena; Catherine Lein; C William Given; Barbara Given; John Goddeeris
Journal:  J Gen Intern Med       Date:  2006-07       Impact factor: 5.128

4.  Somatisation disorder and its associated factors in multiethnic primary care clinic attenders.

Authors:  E M Khoo; N J Mathers; S A McCarthy; W Y Low
Journal:  Int J Behav Med       Date:  2012-06

5.  The Othmer and DeSouza test for screening of somatisation disorder: is it useful in general practice?

Authors:  P Zaballa; Y Crega; G Grandes; C Peralta
Journal:  Br J Gen Pract       Date:  2001-03       Impact factor: 5.386

6.  Treating Somatic Fixation: A Biopsychosocial Approach: When patients express emotions with physical symptoms.

Authors:  S H McDaniel; T Campbell; D Seaburn
Journal:  Can Fam Physician       Date:  1991-02       Impact factor: 3.275

7.  Diagnostic accuracy of predicting somatization from patients' ICD-9 diagnoses.

Authors:  Robert C Smith; Joseph C Gardiner; Zhehui Luo; Kathryn Rost
Journal:  Psychosom Med       Date:  2009-03-17       Impact factor: 4.312

8.  Costs of an intervention for primary care patients with medically unexplained symptoms: a randomized controlled trial.

Authors:  Zhehui Luo; John Goddeeris; Joseph C Gardiner; Robert C Smith
Journal:  Psychiatr Serv       Date:  2007-08       Impact factor: 3.084

9.  Somatization in Family Practice: Comparing 5 Methods of Classification.

Authors:  Denis J. Lynch; Angele McGrady; Rollin Nagel; Connie Zsembik
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-06

Review 10.  Treating patients with medically unexplained symptoms in primary care.

Authors:  Robert C Smith; Catherine Lein; Clare Collins; Judith S Lyles; Barbara Given; Francesca C Dwamena; John Coffey; AnneMarie Hodges; Joseph C Gardiner; John Goddeeris; C William Given
Journal:  J Gen Intern Med       Date:  2003-06       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.